• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Juventas completes phase I trial for heart failure

Juventas completes phase I trial for heart failure

April 27, 2011
CenterWatch Staff

Juventas Therapeutics, a clinical-stage regenerative medicine company that develops therapies for cardiovascular disease, has completed a phase I clinical trial evaluating the safety and preliminary efficacy of JVS-100 for treatment of patients with heart failure. 

The trial enrolled 17 New York Heart Association Class III heart failure patients, with left ventricular ejection fractions less than 40% and an average time from heart attack of 7.3 years.  Three escalating JVS-100 doses were evaluated: 5 mg (cohort 1), 15 mg (cohort 2) and 30 mg (cohort 3).  The primary safety endpoint was the number of major adverse cardiac events (MACE) at 30 days. Efficacy was assessed as changes from baseline in: echocardiographic parameters, cardiac perfusion via SPECT and clinical parameters including NYHA class, 6 minute walk distance (6MWd) and quality of life score (QOL).  Safety data has been collected for all 17-patients and 4-month efficacy data has been collected from cohort 1 and 2 patients.

The primary safety endpoint for the trial has been met with no adverse events likely related to drug.  At 4 months post-therapy, patients are demonstrating dose-dependent improvements in all clinical parameters with clinically relevant improvements compared to baseline in QOL and 6MWd for patients from cohort 2.  At 1-month after dosing in cohort 3 patients are showing similar clinically relevant improvements in QOL and 6MWd with some patients improving a full New York Heart Association class.

 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing